Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors.
A previous study from this laboratory demonstrated that treatment of pregnant mice with 3-methylcholanthrene (MC) caused lung tumors in the offspring at 1 year after birth, the incidence of which correlated with fetal inducibility of Cyp1a1. Analysis by PCR amplification and allele-specific hybridization (ASO) of paraffin-embedded tumors generated from that study revealed the presence of point mutations in exon 1 of the Ki-ras gene. This work has now been expanded by PCR amplification and ASO analysis of 31 additional lesions. Point mutations were found in 37 of the 47 (79%) lesions analyzed in this and the previous study, the majority of which were G-->T transversions in the first or second base of codon 12. The mutational spectrum appeared to be dependent on the relative stage of differentiation of the lesion, as both the incidence of mutation and type of mutation produced correlated with malignant progression. Mutations occurred in 60% of the hyperplasias, 80% of the adenomas and 100% of the adenocarcinomas. In the lesions with mutations, GLY12-->CYS12 transversions occurred in 100% of the hyperplasias, 42% of the adenomas and 14% of the adenocarcinomas. The GLY12-->VAL12 transversions occurred in none of the hyperplasias, 42% of the adenomas and 57% of the adenocarcinomas. The remaining mutations, which consisted of ASP12 transitions and ARG13 transversions, occurred only in adenomas (17%) and adenocarcinomas (29%). Between this study and our previous analyses, the identity of the mutations obtained by ASO were confirmed by sequence analysis of eight of the 37 lesions that harbored mutations at the Ki-ras gene locus. There were no differences in the type or incidence of mutations relative to the metabolic phenotype or sex of the mice. These data suggest that mutational activation of the Ki-ras gene locus is an early event in transplacental lung tumorigenesis, and that the type of mutations produced by exposure to chemical carcinogens can influence the carcinogenic potential of the tumor. This may have prognostic significance in determining the malignant progression of the neoplasm.
Leone-Kabler
S
S
Department of Cancer Biology, Bowman Gray School of Medicine, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA.
Wessner
L L
LL
McEntee
M F
MF
D'Agostino
R B
RB
Miller
M S
MS
D000818:Animals; D015152:Blotting, Northern; D002273:Carcinogens / Q000493:pharmacokinetics / Q000633:toxicity*; D019363:Cytochrome P-450 CYP1A1 / Q000096:biosynthesis / Q000235:genetics; D005260:Female; D011905:Genes, ras; D008175:Lung Neoplasms / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology*; D008297:Male; D008431:Maternal-Fetal Exchange; D008748:Methylcholanthrene / Q000493:pharmacokinetics / Q000633:toxicity*; D051379:Mice; D008811:Mice, Inbred DBA; D009154:Mutation; D009367:Neoplasm Staging; D010641:Phenotype; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D012334:RNA, Neoplasm / Q000032:analysis; D012737:Sex Factors; D015398:Signal Transduction / Q000502:physiology
D002273:Carcinogens; D012334:RNA, Neoplasm; D008748:Methylcholanthrene; D019363:Cytochrome P-450 CYP1A1